LabCorp, Hit With Slumping Volume, Is 'Very Anxious' to Expand 'Genetic Portfolio'

In the fourth quarter around 37 percent, or $407,000, of LabCorp's total revenue of $1.16 million came from genomic, esoteric, and anatomic pathology tests. CEO David King said he wants that to be 40 percent in three or five years.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.